|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPD |
Gene summary for CPD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPD | Gene ID | 1362 |
| Gene name | carboxypeptidase D | |
| Gene Alias | GP180 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | O75976 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1362 | CPD | LZE2T | Human | Esophagus | ESCC | 5.59e-08 | 5.23e-01 | 0.082 |
| 1362 | CPD | LZE4T | Human | Esophagus | ESCC | 1.60e-10 | 2.34e-01 | 0.0811 |
| 1362 | CPD | LZE5T | Human | Esophagus | ESCC | 1.99e-06 | 2.05e+00 | 0.0514 |
| 1362 | CPD | LZE7T | Human | Esophagus | ESCC | 1.97e-04 | 2.11e-01 | 0.0667 |
| 1362 | CPD | LZE20T | Human | Esophagus | ESCC | 2.50e-02 | 1.44e-02 | 0.0662 |
| 1362 | CPD | LZE22T | Human | Esophagus | ESCC | 1.43e-03 | 1.36e-01 | 0.068 |
| 1362 | CPD | LZE24T | Human | Esophagus | ESCC | 1.85e-17 | 5.22e-01 | 0.0596 |
| 1362 | CPD | LZE21T | Human | Esophagus | ESCC | 1.43e-05 | 3.37e-01 | 0.0655 |
| 1362 | CPD | LZE6T | Human | Esophagus | ESCC | 2.67e-04 | 4.78e-02 | 0.0845 |
| 1362 | CPD | P2T-E | Human | Esophagus | ESCC | 1.33e-20 | 4.56e-01 | 0.1177 |
| 1362 | CPD | P4T-E | Human | Esophagus | ESCC | 5.68e-09 | 2.76e-01 | 0.1323 |
| 1362 | CPD | P5T-E | Human | Esophagus | ESCC | 6.48e-04 | 9.52e-02 | 0.1327 |
| 1362 | CPD | P8T-E | Human | Esophagus | ESCC | 3.57e-36 | 9.35e-01 | 0.0889 |
| 1362 | CPD | P9T-E | Human | Esophagus | ESCC | 2.19e-05 | 1.78e-01 | 0.1131 |
| 1362 | CPD | P10T-E | Human | Esophagus | ESCC | 5.11e-12 | 1.73e-02 | 0.116 |
| 1362 | CPD | P11T-E | Human | Esophagus | ESCC | 1.29e-02 | 4.13e-01 | 0.1426 |
| 1362 | CPD | P12T-E | Human | Esophagus | ESCC | 5.80e-24 | 3.26e-01 | 0.1122 |
| 1362 | CPD | P15T-E | Human | Esophagus | ESCC | 1.36e-19 | 5.10e-01 | 0.1149 |
| 1362 | CPD | P16T-E | Human | Esophagus | ESCC | 1.16e-14 | 3.05e-01 | 0.1153 |
| 1362 | CPD | P17T-E | Human | Esophagus | ESCC | 4.09e-07 | 2.15e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
| GO:00464672 | Oral cavity | OSCC | membrane lipid biosynthetic process | 77/7305 | 142/18723 | 1.63e-04 | 1.13e-03 | 77 |
| GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
| GO:00442426 | Oral cavity | OSCC | cellular lipid catabolic process | 104/7305 | 214/18723 | 2.61e-03 | 1.15e-02 | 104 |
| GO:00066641 | Oral cavity | OSCC | glycolipid metabolic process | 53/7305 | 100/18723 | 3.09e-03 | 1.33e-02 | 53 |
| GO:19035091 | Oral cavity | OSCC | liposaccharide metabolic process | 53/7305 | 101/18723 | 4.06e-03 | 1.66e-02 | 53 |
| GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
| GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
| GO:006053715 | Oral cavity | EOLP | muscle tissue development | 77/2218 | 403/18723 | 1.37e-05 | 2.31e-04 | 77 |
| GO:001470614 | Oral cavity | EOLP | striated muscle tissue development | 72/2218 | 384/18723 | 4.87e-05 | 6.43e-04 | 72 |
| GO:00605384 | Oral cavity | EOLP | skeletal muscle organ development | 35/2218 | 166/18723 | 4.65e-04 | 4.08e-03 | 35 |
| GO:00075195 | Oral cavity | EOLP | skeletal muscle tissue development | 32/2218 | 155/18723 | 1.15e-03 | 8.37e-03 | 32 |
| GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
| GO:006053723 | Oral cavity | NEOLP | muscle tissue development | 75/2005 | 403/18723 | 1.22e-06 | 3.15e-05 | 75 |
| GO:001470621 | Oral cavity | NEOLP | striated muscle tissue development | 69/2005 | 384/18723 | 1.11e-05 | 2.06e-04 | 69 |
| GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
| GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
| GO:000751912 | Oral cavity | NEOLP | skeletal muscle tissue development | 29/2005 | 155/18723 | 1.97e-03 | 1.32e-02 | 29 |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPD | SNV | Missense_Mutation | rs375764127 | c.1927N>G | p.Gln643Glu | p.Q643E | O75976 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CPD | SNV | Missense_Mutation | c.3388N>A | p.His1130Asn | p.H1130N | O75976 | protein_coding | tolerated(0.14) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CPD | SNV | Missense_Mutation | novel | c.4027N>A | p.Glu1343Lys | p.E1343K | O75976 | protein_coding | deleterious_low_confidence(0.02) | benign(0.073) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CPD | SNV | Missense_Mutation | c.2153N>C | p.Arg718Thr | p.R718T | O75976 | protein_coding | tolerated(0.74) | benign(0.01) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CPD | SNV | Missense_Mutation | novel | c.2509N>T | p.Pro837Ser | p.P837S | O75976 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| CPD | SNV | Missense_Mutation | novel | c.3812N>T | p.Ser1271Leu | p.S1271L | O75976 | protein_coding | tolerated(0.22) | benign(0.076) | TCGA-OL-A66L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CPD | insertion | In_Frame_Ins | novel | c.2107_2108insATCAAAAACTTT | p.Ile703delinsAsnGlnLysLeuLeu | p.I703delinsNQKLL | O75976 | protein_coding | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | ||
| CPD | insertion | Frame_Shift_Ins | novel | c.2109_2110insT | p.Ala704CysfsTer15 | p.A704Cfs*15 | O75976 | protein_coding | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | ||
| CPD | SNV | Missense_Mutation | rs377211802 | c.1088N>A | p.Arg363Gln | p.R363Q | O75976 | protein_coding | tolerated(0.68) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CPD | SNV | Missense_Mutation | novel | c.2840N>C | p.Val947Ala | p.V947A | O75976 | protein_coding | tolerated(0.52) | benign(0.171) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1362 | CPD | ENZYME, DRUGGABLE GENOME, PROTEASE | ANTISERUM | 9490632 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |